NEW YORK, March 18, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of GW Pharmaceuticals plc (“GW Pharmaceuticals”) (NASDAQ:GWPH) between December 4, 2014 and January 8, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to: http://zlk.9nl.com/gw-pharmaceuticals.
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company lacked effective internal financial controls; (ii) the Company lacked effective controls over completeness and valuation of clinical trial accruals; and (iii) as a result of the foregoing, Defendants’ statements about GW Pharmaceuticals’ business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
In its 2015 Annual Report, GW Pharmaceuticals disclosed the discovery of a material weakness in its internal control over financial reporting for the year ended September 30, 2015. The Company noted that “management does not have sufficiently precise controls to evaluate the completeness and accuracy of the calculation of clinical trial accruals due to the incorrect allocation of expenditure to clinical studies.” On this news, GW Pharmaceuticals stock fell $3.55, or nearly 6%, to close at $56.31 per share on January 11, 2016.
If you suffered a loss in GW Pharmaceuticals you have until March 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/gw-pharmaceuticals.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


John Ternus Signals Apple’s Future with Product-First AI Strategy
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos
Want to cut your energy bills? Here’s how five experts are doing it
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 



